RESUMO
AIMS: Implantable loop recorders (ILRs) are increasingly being used for long-term cardiac monitoring in different clinical settings. The aim of this study was to investigate the real-world performance of ILRs-including the time to diagnosis- in unselected patients with different ILR indications. METHODS AND RESULTS: In this multicenter, observational study, 871 patients with an indication of pre-syncope/syncope (61.9%), unexplained palpitations (10.4%), and atrial fibrillation (AF) detection with a history of cryptogenic stroke (CS) (27.7%) underwent ILR implantation. The median follow-up was 28.8 ± 12.9 months. In the presyncope/syncope group, 167 (31%) received a diagnosis established by the device. Kaplan-Meier estimates indicated that 16.9% of patients had a diagnosis at 6 months, and the proportion increased to 22.5% at 1 year. Of 91 patients with palpitations, 20 (22%) received a diagnosis based on the device. The diagnosis established at 12.2% of patients at 6 months, and the proportion increased to 13.3% at 1 year. Among 241 patients with CS, 47 (19.5%) were diagnosed with AF. The diagnostic yield of the device was 10.4% at 6 months and 12.4% at 1 year. In all cases, oral anticoagulation was initiated. Overall, ILR diagnosis altered the therapeutic strategy in 26.1% in presyncope/syncope group, 2.2% in palpitations group, and 3.7% in CS group in addition to oral anticoagulation initiation. CONCLUSIONS: In this real-world patient population, ILR determines diagnosis and initiates a new therapeutic management in nearly one fourth of patients. ILR implantation is valuable in the evaluation of patients with unexplained presyncope/syncope, CS and palpitations.
RESUMO
BACKGROUND: We sought to evaluate for the first time in humans the safety and feasibility of right ventricular (RV) thermography in patients with coronary artery disease (CAD) and in patients after heart transplantation (Tx), in comparison to subjects without structural heart disease (controls). METHODS: Ninety-one RV thermography procedures were performed in 16 patients with CAD, 19 hearttransplant recipients and 6 patients without structural heart disease. We recorded the temperature of the RV intracavitary blood and RV endocardial septum, and calculated their difference using a dedicated commercially available thermography catheter. RESULTS: No complications were observed. CAD patients had a significantly higher temperature difference (0.19 +/- 0.11 degrees C) compared to both Tx patients (0.10 +/- 0.06 degrees C) and controls (0.07 +/- 0.04 degrees C) (p < 0.0001 and p = 0.003, respectively), whereas there was no significant difference between the Tx patients and controls (p = 0.65). CONCLUSION: RV thermography in humans is feasible and safe. Patients with stable CAD present a significantly higher temperature difference in the RV endocardium compared to controls; clinically stable transplant recipients have temperatures similar to controls. This novel method corroborates previous findings supporting the inflammatory hypothesis of coronary atherosclerosis.